151 related articles for article (PubMed ID: 27781494)
1. Novel FFA1 (GPR40) agonists containing spirocyclic periphery: polar azine periphery as a driver of potency.
Krasavin M; Lukin A; Bagnyukova D; Zhurilo N; Zahanich I; Zozulya S
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):29-36. PubMed ID: 27781494
[TBL] [Abstract][Full Text] [Related]
2. Polar aromatic periphery increases agonist potency of spirocyclic free fatty acid receptor (GPR40) agonists inspired by LY2881835.
Krasavin M; Lukin A; Bagnyukova D; Zhurilo N; Golovanov A; Zozulya S; Zahanich I; Moore D; Tikhonova IG
Eur J Med Chem; 2017 Feb; 127():357-368. PubMed ID: 28076825
[TBL] [Abstract][Full Text] [Related]
3. Free fatty acid receptor 1 (GPR40) agonists containing spirocyclic periphery inspired by LY2881835.
Krasavin M; Lukin A; Bagnyukova D; Zhurilo N; Zahanich I; Zozulya S; Ihalainen J; Forsberg MM; Lehtonen M; Rautio J; Moore D; Tikhonova IG
Bioorg Med Chem; 2016 Nov; 24(21):5481-5494. PubMed ID: 27647366
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and Structure-activity relationship studies of new thiazole-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
Li Z; Qiu Q; Xu X; Wang X; Jiao L; Su X; Pan M; Huang W; Qian H
Eur J Med Chem; 2016 May; 113():246-57. PubMed ID: 26945112
[TBL] [Abstract][Full Text] [Related]
5. Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold.
Krasavin M; Lukin A; Zhurilo N; Kovalenko A; Zahanich I; Zozulya S; Moore D; Tikhonova IG
Bioorg Med Chem; 2016 Jul; 24(13):2954-2963. PubMed ID: 27229618
[TBL] [Abstract][Full Text] [Related]
6. Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes.
Bharate SB; Nemmani KV; Vishwakarma RA
Expert Opin Ther Pat; 2009 Feb; 19(2):237-64. PubMed ID: 19441920
[TBL] [Abstract][Full Text] [Related]
7. Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties.
Christiansen E; Urban C; Grundmann M; Due-Hansen ME; Hagesaether E; Schmidt J; Pardo L; Ullrich S; Kostenis E; Kassack M; Ulven T
J Med Chem; 2011 Oct; 54(19):6691-703. PubMed ID: 21854074
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and evaluation of a series of novel phenylpropanoic acid derivatives agonists for the FFA1.
Yang J; Gu E; Yan T; Shen D; Feng B; Tang C
Chem Biol Drug Des; 2019 May; 93(5):900-909. PubMed ID: 30657643
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and structure-activity relationship studies of GPR40 agonists containing amide linker.
Chen T; Ning M; Ye Y; Wang K; Leng Y; Shen J
Eur J Med Chem; 2018 May; 152():175-194. PubMed ID: 29705709
[TBL] [Abstract][Full Text] [Related]
10. GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.
Chen C; Li H; Long YQ
Bioorg Med Chem Lett; 2016 Dec; 26(23):5603-5612. PubMed ID: 27825762
[TBL] [Abstract][Full Text] [Related]
11. Free fatty acid receptor 1 (FFA1/GPR40) agonists: mesylpropoxy appendage lowers lipophilicity and improves ADME properties.
Christiansen E; Due-Hansen ME; Urban C; Grundmann M; Schröder R; Hudson BD; Milligan G; Cawthorne MA; Kostenis E; Kassack MU; Ulven T
J Med Chem; 2012 Jul; 55(14):6624-8. PubMed ID: 22724451
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a Potent Free Fatty Acid 1 Receptor Agonist with Low Lipophilicity, Low Polar Surface Area, and Robust in Vivo Efficacy.
Hansen SV; Christiansen E; Urban C; Hudson BD; Stocker CJ; Due-Hansen ME; Wargent ET; Shimpukade B; Almeida R; Ejsing CS; Cawthorne MA; Kassack MU; Milligan G; Ulven T
J Med Chem; 2016 Mar; 59(6):2841-6. PubMed ID: 26928019
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel potent GPR40 agonists containing imidazo[1,2-a]pyridine core as antidiabetic agents.
Ye Z; Liu C; Zou F; Cai Y; Chen B; Zou Y; Mo J; Han T; Huang W; Qiu Q; Qian H
Bioorg Med Chem; 2020 Jul; 28(13):115574. PubMed ID: 32546302
[TBL] [Abstract][Full Text] [Related]
14. Continued SAR exploration of 1,2,4-thiadiazole-containing scaffolds in the design of free fatty acid receptor 1 (GPR40) agonists.
Krasavin M; Lukin A; Bakholdina A; Zhurilo N; Onopchenko O; Borysko P; Zozulya S; Moore D; Tikhonova IG
Eur J Med Chem; 2017 Nov; 140():229-238. PubMed ID: 28938138
[TBL] [Abstract][Full Text] [Related]
15. Recent Advances in Development of GPR40 Modulators (FFA1/FFAR1): An Emerging Target for Type 2 Diabetes.
Sharma N; Bhagat S; Chundawat TS
Mini Rev Med Chem; 2017; 17(11):947-958. PubMed ID: 28117025
[TBL] [Abstract][Full Text] [Related]
16. Free fatty acid receptor agonists for the treatment of type 2 diabetes: drugs in preclinical to phase II clinical development.
Li Z; Qiu Q; Geng X; Yang J; Huang W; Qian H
Expert Opin Investig Drugs; 2016 Aug; 25(8):871-90. PubMed ID: 27171154
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARγ and PPARδ.
Li Z; Zhou Z; Deng F; Li Y; Zhang D; Zhang L
Eur J Med Chem; 2018 Nov; 159():267-276. PubMed ID: 30296685
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel free fatty acid receptor 1 agonists bearing triazole core via click chemistry.
Li Z; Yang J; Wang X; Li H; Liu C; Wang N; Huang W; Qian H
Bioorg Med Chem; 2016 Nov; 24(21):5449-5454. PubMed ID: 27624524
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of novel dual FFA1 (GPR40)/PPARδ agonists as potential anti-diabetic agents.
Li Z; Hu L; Wang X; Zhou Z; Deng L; Xu Y; Zhang L
Bioorg Chem; 2019 Nov; 92():103254. PubMed ID: 31518760
[TBL] [Abstract][Full Text] [Related]
20. Exploration of the nitrogen heterocyclic periphery around the core of the advanced FFA1 agonist fasiglifam (TAK-875).
Lukin A; Bakholdina A; Zhurilo N; Onopchenko O; Zhuravel E; Zozulya S; Gureev M; Safrygin A; Krasavin M
Arch Pharm (Weinheim); 2021 Apr; 354(4):e2000275. PubMed ID: 33270252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
